vs
布鲁克（BRKR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
布鲁克的季度营收约是Revvity的1.3倍（$977.2M vs $772.1M），Revvity净利率更高（12.7% vs 2.7%，领先10.1%），Revvity同比增速更快（5.9% vs -0.2%），布鲁克自由现金流更多（$207.2M vs $161.8M），过去两年布鲁克的营收复合增速更高（16.4% vs 9.0%）
布鲁克公司是美国科学仪器制造商，总部位于马萨诸塞州比勒里卡，为公开上市企业。公司产品服务于分子与材料研究、工业及应用分析领域，旗下设有布鲁克科学仪器、布鲁克能源与超导技术（BEST）两大业务板块。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BRKR vs RVTY — 直观对比
营收规模更大
BRKR
是对方的1.3倍
$772.1M
营收增速更快
RVTY
高出6.1%
-0.2%
净利率更高
RVTY
高出10.1%
2.7%
自由现金流更多
BRKR
多$45.4M
$161.8M
两年增速更快
BRKR
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $977.2M | $772.1M |
| 净利润 | $26.0M | $98.4M |
| 毛利率 | 46.0% | — |
| 营业利润率 | 7.8% | 14.5% |
| 净利率 | 2.7% | 12.7% |
| 营收同比 | -0.2% | 5.9% |
| 净利润同比 | 89.8% | 3.9% |
| 每股收益（稀释后） | $0.10 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BRKRRVTY
| Q4 25 | $977.2M | $772.1M | ||
| Q3 25 | $860.5M | $698.9M | ||
| Q2 25 | $797.4M | $720.3M | ||
| Q1 25 | $801.4M | $664.8M | ||
| Q4 24 | $979.6M | $729.4M | ||
| Q3 24 | $864.4M | $684.0M | ||
| Q2 24 | $800.7M | $691.7M | ||
| Q1 24 | $721.7M | $649.9M |
净利润BRKRRVTY
| Q4 25 | $26.0M | $98.4M | ||
| Q3 25 | $-59.6M | $46.7M | ||
| Q2 25 | $7.6M | $53.9M | ||
| Q1 25 | $17.4M | $42.2M | ||
| Q4 24 | $13.7M | $94.6M | ||
| Q3 24 | $40.9M | $94.4M | ||
| Q2 24 | $7.6M | $55.4M | ||
| Q1 24 | $50.9M | $26.0M |
毛利率BRKRRVTY
| Q4 25 | 46.0% | — | ||
| Q3 25 | 44.1% | 53.6% | ||
| Q2 25 | 44.9% | 54.5% | ||
| Q1 25 | 48.8% | 56.5% | ||
| Q4 24 | 50.4% | — | ||
| Q3 24 | 48.4% | 56.3% | ||
| Q2 24 | 48.0% | 55.7% | ||
| Q1 24 | 48.9% | 54.6% |
营业利润率BRKRRVTY
| Q4 25 | 7.8% | 14.5% | ||
| Q3 25 | -6.0% | 11.7% | ||
| Q2 25 | 1.5% | 12.6% | ||
| Q1 25 | 4.0% | 10.9% | ||
| Q4 24 | 7.4% | 16.3% | ||
| Q3 24 | 7.9% | 14.3% | ||
| Q2 24 | 6.0% | 12.4% | ||
| Q1 24 | 9.0% | 6.8% |
净利率BRKRRVTY
| Q4 25 | 2.7% | 12.7% | ||
| Q3 25 | -6.9% | 6.7% | ||
| Q2 25 | 1.0% | 7.5% | ||
| Q1 25 | 2.2% | 6.4% | ||
| Q4 24 | 1.4% | 13.0% | ||
| Q3 24 | 4.7% | 13.8% | ||
| Q2 24 | 0.9% | 8.0% | ||
| Q1 24 | 7.1% | 4.0% |
每股收益（稀释后）BRKRRVTY
| Q4 25 | $0.10 | $0.86 | ||
| Q3 25 | $-0.41 | $0.40 | ||
| Q2 25 | $0.05 | $0.46 | ||
| Q1 25 | $0.11 | $0.35 | ||
| Q4 24 | $0.09 | $0.77 | ||
| Q3 24 | $0.27 | $0.77 | ||
| Q2 24 | $0.05 | $0.45 | ||
| Q1 24 | $0.35 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $298.8M | $919.9M |
| 总债务越低越好 | $1.9B | — |
| 股东权益账面价值 | $2.5B | $7.3B |
| 总资产 | $6.2B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.76× | — |
8季度趋势，按日历期对齐
现金及短期投资BRKRRVTY
| Q4 25 | $298.8M | $919.9M | ||
| Q3 25 | $293.1M | $931.4M | ||
| Q2 25 | $92.0M | $991.8M | ||
| Q1 25 | $184.2M | $1.1B | ||
| Q4 24 | $183.4M | $1.2B | ||
| Q3 24 | $148.1M | $1.2B | ||
| Q2 24 | $169.7M | $2.0B | ||
| Q1 24 | $340.1M | $1.7B |
总债务BRKRRVTY
| Q4 25 | $1.9B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $1.4B | — |
股东权益BRKRRVTY
| Q4 25 | $2.5B | $7.3B | ||
| Q3 25 | $2.4B | $7.4B | ||
| Q2 25 | $1.8B | $7.6B | ||
| Q1 25 | $1.8B | $7.6B | ||
| Q4 24 | $1.8B | $7.7B | ||
| Q3 24 | $1.8B | $7.9B | ||
| Q2 24 | $1.8B | $7.9B | ||
| Q1 24 | $1.4B | $7.8B |
总资产BRKRRVTY
| Q4 25 | $6.2B | $12.2B | ||
| Q3 25 | $6.4B | $12.1B | ||
| Q2 25 | $6.3B | $12.4B | ||
| Q1 25 | $5.9B | $12.4B | ||
| Q4 24 | $5.8B | $12.4B | ||
| Q3 24 | $6.1B | $12.8B | ||
| Q2 24 | $5.9B | $13.4B | ||
| Q1 24 | $4.5B | $13.4B |
负债/权益比BRKRRVTY
| Q4 25 | 0.76× | — | ||
| Q3 25 | 0.83× | — | ||
| Q2 25 | 1.34× | — | ||
| Q1 25 | 1.15× | — | ||
| Q4 24 | 1.18× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | 1.21× | — | ||
| Q1 24 | 0.97× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $207.2M | $161.8M |
| 自由现金流率自由现金流/营收 | 21.2% | 21.0% |
| 资本支出强度资本支出/营收 | 2.3% | 2.6% |
| 现金转化率经营现金流/净利润 | 8.84× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $43.3M | $509.4M |
8季度趋势，按日历期对齐
经营现金流BRKRRVTY
| Q4 25 | $229.8M | $182.0M | ||
| Q3 25 | $-33.2M | $138.5M | ||
| Q2 25 | $-127.5M | $134.3M | ||
| Q1 25 | $65.0M | $128.2M | ||
| Q4 24 | $190.0M | $174.2M | ||
| Q3 24 | $38.4M | $147.9M | ||
| Q2 24 | $1.1M | $158.6M | ||
| Q1 24 | $21.8M | $147.6M |
自由现金流BRKRRVTY
| Q4 25 | $207.2M | $161.8M | ||
| Q3 25 | $-54.1M | $120.0M | ||
| Q2 25 | $-148.8M | $115.5M | ||
| Q1 25 | $39.0M | $112.2M | ||
| Q4 24 | $153.3M | $149.8M | ||
| Q3 24 | $5.8M | $125.6M | ||
| Q2 24 | $-23.5M | $136.6M | ||
| Q1 24 | $400.0K | $129.7M |
自由现金流率BRKRRVTY
| Q4 25 | 21.2% | 21.0% | ||
| Q3 25 | -6.3% | 17.2% | ||
| Q2 25 | -18.7% | 16.0% | ||
| Q1 25 | 4.9% | 16.9% | ||
| Q4 24 | 15.6% | 20.5% | ||
| Q3 24 | 0.7% | 18.4% | ||
| Q2 24 | -2.9% | 19.7% | ||
| Q1 24 | 0.1% | 20.0% |
资本支出强度BRKRRVTY
| Q4 25 | 2.3% | 2.6% | ||
| Q3 25 | 2.4% | 2.6% | ||
| Q2 25 | 2.7% | 2.6% | ||
| Q1 25 | 3.2% | 2.4% | ||
| Q4 24 | 3.7% | 3.4% | ||
| Q3 24 | 3.8% | 3.3% | ||
| Q2 24 | 3.1% | 3.2% | ||
| Q1 24 | 3.0% | 2.7% |
现金转化率BRKRRVTY
| Q4 25 | 8.84× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | -16.78× | 2.49× | ||
| Q1 25 | 3.74× | 3.03× | ||
| Q4 24 | 13.87× | 1.84× | ||
| Q3 24 | 0.94× | 1.57× | ||
| Q2 24 | 0.14× | 2.87× | ||
| Q1 24 | 0.43× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BRKR
| Bsi Nano | $309.1M | 32% |
| Bsi Biospin | $267.0M | 27% |
| Other | $179.9M | 18% |
| Transferred Over Time | $142.5M | 15% |
| Energy And Supercon Technologies | $69.5M | 7% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
